Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin prophylaxis for prevention of catheter-associated urinary tract infection in short-term bladder catheterization
IRCT20251019067683N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciprofloxacin in urinary tract infection (UTI) (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Fever, Urinary symptoms and 1 more. Started Nov 2025; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on IRCT20251019067683N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251019067683N1.